<?xml version="1.0" encoding='utf-8' ?>
<nspnews type="text">
<version>v8.0</version>
<date>2023-05-03 15:26:11</date>
<action>I</action>
<registdate>2023-05-03 14:50:05</registdate>
<modifydate>2023-05-03 15:25:37</modifydate>
<publishdate>2023-05-03 15:26:07</publishdate>
<embargo>N</embargo>
<newsid>635219</newsid>
<orgid></orgid>
<language>KR</language>
<category1>21</category1>
<category2>2102</category2>
<category1_name>의학/건강</category1_name>
<category2_name>제약/바이오</category2_name>
<statusID>1</statusID>
<saleID>N</saleID>
<formatID>1</formatID>
<typeID>7</typeID>
<newsSubject><![CDATA[동아에스티 비알콜성지방간염 치료제, 미국 FDA 임상 2상 승인]]></newsSubject>
<newsSummary><![CDATA[]]></newsSummary>
<newsTag><![CDATA[동아에스티(170900),비알콜성지방간염,동아에스티임상,지방간치료제,미국식품의약국]]></newsTag>
<newsLinks><![CDATA[]]></newsLinks>
<news_prolog><![CDATA[(서울=NSP통신) 김다은 기자 =]]></news_prolog>
<news1><![CDATA[﻿동아에스티 자회사 뉴로보 파마슈티컬스가 미국 식품의약국(FDA)로부터 ‘DA-1241’의 임상 2상을 승인받았다. 

DA-1241은 뉴로보 파마슈티컬스가 개발 중인 ‘NASH(Non-Alcoholic Steatohepatitis, 비알콜성지방간염)’ 치료제. NASH는 알코올 섭취와 관계없이 간세포에 중성지방이 축적되는 질환이다. 

DA-1241의 미국 임상 2상은 올해 3분기 내 개시될 예정이다. 종료는 내년 하반기다.]]></news1>
<news2_title><![CDATA[]]></news2_title>
<news2><![CDATA[]]></news2>
<news3_title><![CDATA[]]></news3_title>
<news3><![CDATA[]]></news3>
<news4_title><![CDATA[]]></news4_title>
<news4><![CDATA[]]></news4>
<news5_title><![CDATA[]]></news5_title>
<news5><![CDATA[]]></news5>
<news_epilog_info><![CDATA[]]></news_epilog_info>
<news_epilog_byline><![CDATA[NSP통신 김다은 기자(ekdms8381@nspna.com)]]></news_epilog_byline>
<news_epilog><![CDATA[ⓒ한국의 경제뉴스통신사 NSP통신·NSP TV. 무단전재-재배포 금지.]]></news_epilog>
<imageL><![CDATA[https://file.nspna.com/news/2023/05/03/20230503145619_635219_0.jpg]]></imageL>
<imageP><![CDATA[https://file.nspna.com/news/2023/05/03/photo_20230503145619_635219_0.jpg]]></imageP>
<image1><![CDATA[https://file.nspna.com/news/2023/05/03/20230503145619_635219_1.jpg]]></image1>
<image2><![CDATA[]]></image2>
<image3><![CDATA[]]></image3>
<image4><![CDATA[]]></image4>
<image5><![CDATA[]]></image5>
<image1_place><![CDATA[l]]></image1_place>
<image2_place><![CDATA[c]]></image2_place>
<image3_place><![CDATA[c]]></image3_place>
<image4_place><![CDATA[c]]></image4_place>
<image5_place><![CDATA[c]]></image5_place>
<image1_text><![CDATA[]]></image1_text>
<image2_text><![CDATA[]]></image2_text>
<image3_text><![CDATA[]]></image3_text>
<image4_text><![CDATA[]]></image4_text>
<image5_text><![CDATA[]]></image5_text>
<image1_source><![CDATA[사진 = 동아에스티]]></image1_source>
<image2_source><![CDATA[]]></image2_source>
<image3_source><![CDATA[]]></image3_source>
<image4_source><![CDATA[]]></image4_source>
<image5_source><![CDATA[]]></image5_source>
<vodSite><![CDATA[]]></vodSite>
<vodID><![CDATA[]]></vodID>
<vodTitle><![CDATA[]]></vodTitle>
<vodWidth><![CDATA[]]></vodWidth>
<vodHeight><![CDATA[]]></vodHeight>
<advertorial><![CDATA[]]></advertorial>
<location><![CDATA[서울]]></location>
<teamID>102</teamID>
<teamName><![CDATA[산업경제부]]></teamName>
<writerID>ekdms8381</writerID>
<writerName><![CDATA[김다은]]></writerName>
<writerTitle><![CDATA[기자]]></writerTitle>
<writerEmail><![CDATA[ekdms8381@nspna.com]]></writerEmail>
<writerID2></writerID2>
<writerName2><![CDATA[]]></writerName2>
<writerTitle2><![CDATA[]]></writerTitle2>
<writerEmail2><![CDATA[]]></writerEmail2>
<writerID3></writerID3>
<writerName3><![CDATA[]]></writerName3>
<writerTitle3><![CDATA[]]></writerTitle3>
<writerEmail3><![CDATA[]]></writerEmail3>
</nspnews>
